Insider Selling: Exelixis, Inc. (NASDAQ:EXEL) EVP Sells $1,154,500.00 in Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 25,000 shares of Exelixis stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $46.18, for a total value of $1,154,500.00. Following the transaction, the executive vice president now owns 693,396 shares in the company, valued at $32,021,027.28. This represents a 3.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $45.40 on Monday. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $48.85. The business has a 50-day moving average of $37.23 and a two-hundred day moving average of $35.84. The stock has a market capitalization of $12.51 billion, a P/E ratio of 25.65, a P/E/G ratio of 1.13 and a beta of 0.25.

Institutional Trading of Exelixis

Institutional investors and hedge funds have recently made changes to their positions in the stock. Coppell Advisory Solutions LLC acquired a new stake in shares of Exelixis in the fourth quarter worth about $25,000. Hemington Wealth Management lifted its position in shares of Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock worth $28,000 after buying an additional 522 shares during the last quarter. Colonial Trust Co SC lifted its position in shares of Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after buying an additional 765 shares during the last quarter. Principal Securities Inc. lifted its position in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares during the last quarter. Finally, USA Financial Formulas acquired a new position in shares of Exelixis during the 4th quarter worth about $32,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Guggenheim reiterated a “buy” rating and set a $42.00 price target on shares of Exelixis in a report on Wednesday, February 12th. UBS Group reiterated an “underperform” rating on shares of Exelixis in a report on Thursday, April 17th. JMP Securities reiterated a “market outperform” rating and set a $41.00 price target on shares of Exelixis in a report on Thursday, April 17th. Wells Fargo & Company reiterated a “market outperform” rating on shares of Exelixis in a report on Thursday, April 17th. Finally, Stephens reiterated an “equal weight” rating and set a $29.00 price target on shares of Exelixis in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.76.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.